October 18, 2009
The FDA recently announced the approval of a second HPV vaccine for the U.S. market. Cervarix, manufactured by GlaxoSmithKline, is the sole competitor to rival vaccine Gardasil, produced by Merck & Co. The vaccines differ in the strains of HPV they guard against, but both will fight the two most common strains that cause 70% of cervical cancers. At the same time, however, the FDA also granted approval for Merck’s Gardasil to be used in preventing genital warts (not genital cancer) in boys and men ages 9 through 26. But, do our children need yet another vaccine? You be the judge. Both vaccines are expected to net their respective companies over $1 billion per year in the coming years. [via ABC News]

Share your comments here.
Tweet This
Share on Facebook
Posted by Steven / October 18, 2009 5:25 pm / Permalink / Comments (4) / Trackbacks (0)
September 10, 2009
Since the introduction of their Gardasil vaccine (marketed for the prevention of cervical cancer in women), pharmaceutical giant Merck has been wanting to expand the vaccine’s use to include males. Currently, the vaccine is approved for use in girls and women between the ages of 9 and 26. If Merck has its way Gardasil will be used in boys and men ages 9 to 26 as well. In documents posted online, the FDA said the vaccine prevented genital warts in males 90 percent of the time. Based on this the FDA’s Vaccines and Related Biological Products Advisory Committee is supporting the use of Gardasil in males. However, it is unlikely that the use of the vaccine will prevent a significant amount of penile and anal cancers, compared with cervical cancer. Cancer of the penis and anus are extremely rare, with less than 2,000 cases reported annually. Gardasil was approved for women in 2006 and had sales over $1 billion last year. [via CBS News]
Share your comments here.
Tweet This
Share on Facebook
Posted by Steven / September 10, 2009 10:07 pm / Permalink / Comments (2) / Trackbacks (0)